BCM
AKBA icon

Brookstone Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Brookstone Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-35,892
Closed -$487K – 446
2020
Q2 		$487K Buy
+35,892
New +$371K 0.03% 243

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brookstone Capital Management's AKBA Position: Q3 2020 in Review

Brookstone Capital Management sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 35,892 shares — an estimated $487K sold.

Brookstone Capital Management first reported a position in AKBA in Q2 2020 and held it in 1 quarter. The position peaked at $487K in Q2 2020. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • Brookstone Capital Management reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Brookstone Capital Management sold 35,892 Akebia Therapeutics shares in Q3 2020, an estimated $487K.
  • Brookstone Capital Management first reported a position in Akebia Therapeutics in Q2 2020 and held it in 1 quarter.
  • Brookstone Capital Management's Akebia Therapeutics position peaked at $487K in Q2 2020.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on Brookstone Capital Management's 13F filing for Q3 2020, filed 13 Oct 2020.